PCM
LFCR icon

Palouse Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Palouse Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,068
Closed -$96K – 79
2020
Q1 		$96K Sell
11,068
-2,243
-17% -$23.3K 0.06% 71
2019
Q4 		$151K Sell
13,311
-5,060
-28% -$53.8K 0.06% 85
2019
Q3 		$200K Sell
18,371
-825
-4% -$8.98K 0.07% 101
2019
Q2 		$180K Hold
19,196
– – 0.06% 97
2019
Q1 		$236K Buy
19,196
+786
+4% +$9.6K 0.09% 86
2018
Q4 		$218K Hold
18,410
– – 0.09% 85
2018
Q3 		$265K Buy
18,410
+809
+5% +$11.2K 0.09% 86
2018
Q2 		$262K Buy
17,601
+1,107
+7% +$15.4K 0.09% 87
2018
Q1 		$215K Hold
16,494
– – 0.07% 97
2017
Q4 		$208K Sell
16,494
-1,166
-7% -$14.7K 0.07% 96
2017
Q3 		$229K Buy
17,660
+333
+2% +$4.39K 0.08% 94
2017
Q2 		$257K Sell
17,327
-1,391
-7% -$19.4K 0.09% 81
2017
Q1 		$225K Buy
18,718
+4,495
+32% +$56.9K 0.09% 89
2016
Q4 		$196K Sell
14,223
-233
-2% -$3.23K 0.08% 96
2016
Q3 		$194K Sell
14,456
-140
-1% -$1.7K 0.08% 90
2016
Q2 		$157K Sell
14,596
-390
-3% -$4.3K 0.06% 92
2016
Q1 		$157K Sell
14,986
-1,066
-7% -$11.7K 0.06% 94
2015
Q4 		$190K Sell
16,052
-1,500
-9% -$18.4K 0.07% 107
2015
Q3 		$205K Sell
17,552
-1,124
-6% -$14.9K 0.08% 106
2015
Q2 		$269K Sell
18,676
-803
-4% -$11.6K 0.09% 102
2015
Q1 		$272K Sell
19,479
-1,016
-5% -$14K 0.1% 103
2014
Q4 		$283K Hold
20,495
– – 0.1% 117
2014
Q3 		$251K Hold
20,495
– – 0.1% 116
2014
Q2 		$256K Sell
20,495
-605
-3% -$7.12K 0.09% 114
2014
Q1 		$235K Sell
21,100
-1,840
-8% -$20.2K 0.09% 117
2013
Q4 		$278K Sell
22,940
-375
-2% -$4.48K 0.11% 110
2013
Q3 		$284K Buy
23,315
+75
+0.3% +$1.05K 0.11% 104
2013
Q2 		$307K Buy
+23,240
New +$321K 0.13% 88

Other funds holding LFCR

Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palouse Capital Management's LFCR Position: Q2 2020 in Review

Palouse Capital Management sold out of Lifecore Biomedical (LFCR) in Q2 2020, closing a stake of 11,068 shares — an estimated $96K sold.

Palouse Capital Management first reported a position in LFCR in Q2 2013 and held it in 28 quarters. The position peaked at $307K in Q2 2013. 95 funds tracked by Wall St. Rank hold LFCR as of Q2 2020.

  • Palouse Capital Management reported no remaining Lifecore Biomedical position as of Q2 2020 after selling out during the quarter.
  • Palouse Capital Management sold 11,068 Lifecore Biomedical shares in Q2 2020, an estimated $96K.
  • Palouse Capital Management first reported a position in Lifecore Biomedical in Q2 2013 and held it in 28 quarters.
  • Palouse Capital Management's Lifecore Biomedical position peaked at $307K in Q2 2013.
  • 95 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2020.

Based on Palouse Capital Management's 13F filing for Q2 2020, filed 5 Aug 2020.